Results 41 to 50 of about 1,901 (143)

Viral Reprogramming of Nucleotide Synthesis and Its Impact on Viral Infection

Journal of Medical Virology, Volume 97, Issue 8, August 2025.
ABSTRACT Nucleotides are the building blocks of DNA and RNA. They also play essential roles in various other biological processes, including protein glycosylation, ribosome biogenesis, and cytoskeletal function. The significance of the regulation of nucleotide metabolism has recently gained more attention in many physiological and pathological contexts,
Lara Dsouza, Zhilong Yang
wiley   +1 more source

Duration of Nucleos(t)ide Analogue Treatments in Patients With Chronic Hepatitis B Virus Infection in the United States

Journal of Viral Hepatitis, Volume 32, Issue 8, August 2025.
ABSTRACT Viral hepatitis caused by hepatitis B virus accounts for a significant disease burden. Nucleos(t)ide analogues (NAs) are the standard of care for chronic hepatitis B (CHB) infection; however, treatment is long‐term, and viral eradication resulting in cure is rare. Adherence to NAs is vital for disease control.
Seth Anderson, Vera Gielen, Anna D. Coutinho, Laura Clark, Christopher Bell, Shayon Salehi, Renee Gennarelli, Eileen Farrelly, Dana Stafkey, Robert Gish   +9 more
wiley   +1 more source

Clinical Features of HBV‐Related HCC in Long‐Term NAs‐Treated Versus Untreated Patients

Journal of Cellular and Molecular Medicine, Volume 29, Issue 13, July 2025.
ABSTRACT Patients who receive long‐term anti‐hepatitis B virus (HBV) treatment with nucleos(t)ide analogues (NAs) are still at risk for primary hepatocellular carcinoma (HCC). Aim The purpose of this study was to compare clinical features of HBV‐related HCC in NA‐treated vs. untreated patients.
Yuyu Ye, Yeqiong Zhang, Yunming Tang, Ming Liu, Shibin Xie, Ying Liu   +5 more
wiley   +1 more source

Impact of Socio‐Economic, Behavioural and Clinical Factors on Liver Disease Progression in Individuals With HIV and Hepatitis B

Liver International, Volume 45, Issue 7, July 2025.
ABSTRACT Background and Aims Little is known about the contribution of sociodemographic and behavioural factors to developing liver disease in individuals with an HIV and chronic hepatitis B virus (HBV) co‐infection. We aimed to quantify the impact of these factors on incident liver disease in individuals with HIV/HBV receiving care in the Netherlands.
Clémence Ramier, Anders Boyd, Colette Smit, Rosan van Zoest, Mark A. A. Claassen, Katalin Pogány, Dirk Posthouwer, Theodora E. M. S. de Vries‐Sluijs, Patrizia Carrieri, Marc Van der Valk   +9 more
wiley   +1 more source

Frequency, Severity and Impact of Pegylated Interferon Alpha–Associated Flares in Hepatitis D Infection

Journal of Viral Hepatitis, Volume 32, Issue 4, April 2025.
ABSTRACT We analysed the frequency, severity and impact of hepatitis flares in a large Phase 2 study investigating pegylated interferon‐alfa‐2a (PEG‐IFNa) for the treatment of hepatitis D. In the HIDIT‐II study, 120 patients were treated for 96 weeks with PEG‐IFNa (180 μg weekly) in combination with tenofovir disoproxil fumarate (TDF, 300 mg once daily)
Svenja Hardtke, Cihan Yurdaydin, Florin A. Caruntu, Manuela G. Curescu, Kendal Yalcin, Ulus S. Akarca, Selim Gürel, Stefan Zeuzem, Andreas Erhardt, Stefan Lüth, George V. Papatheodoridis, Kerstin Port, Michael P. Manns, Markus Cornberg, Julia Kahlhöfer, Heiner Wedemeyer   +15 more
wiley   +1 more source

HBV‐Induced Carcinogenesis: Mechanisms, Correlation With Viral Suppression, and Implications for Treatment

Liver International, Volume 45, Issue 1, January 2025.
ABSTRACT Background Chronic hepatitis B virus (HBV) infection is a common but underdiagnosed and undertreated health condition and is the leading cause of hepatocellular carcinoma (HCC) worldwide. HBV (rated a Grade 1 carcinogen by the International Agency for Research on Cancer) drives the transformation of hepatocytes in multiple ways by inducing ...
Thomas Tu, Thomas J. McQuaid, Ira M. Jacobson   +2 more
wiley   +1 more source

Efficacy of Antiviral Therapy in Chronic Hepatitis B Patients With Normal Alanine Aminotransferase: A Systematic Review and Meta‐Analysis

Canadian Journal of Gastroenterology and Hepatology, Volume 2025, Issue 1, 2025.
Background and objectives: The efficacy of antiviral therapy in chronic hepatitis B (CHB) patients with normal alanine aminotransferase (ALT) is controversial. This study aimed to systematically review and analyze antiviral efficacy in ALT‐normal CHB patients. Methods: PubMed, Embase, Web of Science, and the Cochrane Library databases from inception to
Yuting Diao, Yueying Zeng, Zhihao Huang, Chunfang You, Kevork M. Peltekian   +4 more
wiley   +1 more source

Virologic Response at 12 Months of Treatment Predicts Sustained Antiviral Efficacy in Patients with Adefovir-Treated Lamivudine-Resistant Chronic Hepatitis B

Gut and Liver, 2010
Background/Aims: The aim of our study was to define the potential role of virologic response at 12 months of treatment (VR12) in predicting subsequent virologic and clinical outcomes in adefovir (ADV)-treated lamivudine-resistant chronic hepatitis B ...
doaj   +1 more source

Bis[(2,2-dimethylpropanoyloxy)methyl] {[2-(6-amino-9H-purin-9-yl)ethoxy]methyl}phosphonate–succinic acid (2/1)

Acta Crystallographica Section E, 2012
The title compound, C20H32N5O8P·0.5C4H6O4, is composed of two 9-{2-[bis(pivaloyloxymethoxy)phosphinylmethoxy]ethyl}adenine, commonly known as adefovir dipivoxil (AD), molecules linked to the carboxylic acid groups of succinic acid (SA).
Jeong-Myeong Ha, Sungyup Jung, Il Won Kim   +2 more
doaj   +1 more source

Eight‐year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials

Alimentary Pharmacology &Therapeutics, Volume 60, Issue 11-12, Page 1573-1586, December 2024.
In patients with CHB, long‐term treatment with TAF, or with TDF followed by TAF, exhibited favourable safety and tolerability with high rates of viral suppression. No resistance to TAF was detected. Summary Background In two phase 3 studies, tenofovir alafenamide (TAF) showed non‐inferior efficacy versus tenofovir disoproxil fumarate (TDF), with more ...
Maria Buti, Young‐Suk Lim, Henry Lik Yuen Chan, Kosh Agarwal, Patrick Marcellin, Maurizia R. Brunetto, Wan‐Long Chuang, Harry L. A. Janssen, Scott K. Fung, Namiki Izumi, Maciej S. Jablkowski, Dzhamal Abdurakhmanov, Frida Abramov, Hongyuan Wang, Irina Botros, Leland J. Yee, Roberto Mateo, John F. Flaherty, Anu Osinusi, Calvin Q. Pan, X. Shalimar, Wai‐Kay Seto, Edward J. Gane   +22 more
wiley   +1 more source